JP2002513541A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002513541A5 JP2002513541A5 JP2000523554A JP2000523554A JP2002513541A5 JP 2002513541 A5 JP2002513541 A5 JP 2002513541A5 JP 2000523554 A JP2000523554 A JP 2000523554A JP 2000523554 A JP2000523554 A JP 2000523554A JP 2002513541 A5 JP2002513541 A5 JP 2002513541A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- cells
- cell
- nkg2
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 32
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 27
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 17
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 15
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 13
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9725764.6A GB9725764D0 (en) | 1997-12-04 | 1997-12-04 | HLA-E binding |
| GB9725764.6 | 1997-12-04 | ||
| PCT/GB1998/003686 WO1999028748A2 (en) | 1997-12-04 | 1998-12-04 | Hla-e binding |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008314107A Division JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002513541A JP2002513541A (ja) | 2002-05-14 |
| JP2002513541A5 true JP2002513541A5 (cg-RX-API-DMAC10.html) | 2006-01-19 |
| JP4336451B2 JP4336451B2 (ja) | 2009-09-30 |
Family
ID=10823165
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000523554A Expired - Lifetime JP4336451B2 (ja) | 1997-12-04 | 1998-12-04 | Ｈｌａ−ｅ結合 |
| JP2008314107A Expired - Lifetime JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008314107A Expired - Lifetime JP4437160B2 (ja) | 1997-12-04 | 2008-12-10 | Ｈｌａ−ｅ結合 |
| JP2009191564A Expired - Lifetime JP5268828B2 (ja) | 1997-12-04 | 2009-08-21 | Ｈｌａ−ｅ結合 |
| JP2013006244A Abandoned JP2013081478A (ja) | 1997-12-04 | 2013-01-17 | Ｈｌａ−ｅ結合 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7410767B1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP1036327B1 (cg-RX-API-DMAC10.html) |
| JP (4) | JP4336451B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE438096T1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69841020D1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB9725764D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1999028748A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| EP1423140A2 (en) * | 2001-07-31 | 2004-06-02 | Karl Petter Söderström | Compositions and methods for modulation of immune responses |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| CA2541241A1 (en) * | 2003-08-26 | 2005-03-03 | Danmarks Tekniske Universitet | A continuous process for the assembly of macromolecular substances and the subsequent capture and isolation of a macromolecular assembly, and a system suitable for the process |
| EP1766393A4 (en) * | 2004-05-07 | 2008-06-18 | Beckman Coulter Inc | MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS |
| EP2226332A1 (en) | 2004-06-17 | 2010-09-08 | Beckman Coulter, Inc. | Mycobacterium tuberculosis epitopes and methods of use thereof |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| US7932055B2 (en) * | 2006-06-22 | 2011-04-26 | Novo Nordisk A/S | Soluble heterodimeric CD94/NKG2 receptors fusion proteins |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| MX342131B (es) | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| US20150037304A1 (en) * | 2013-03-12 | 2015-02-05 | Sangamo Biosciences, Inc. | Methods and compositions for modification of hla |
| ES2769574T3 (es) | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| WO2015148960A1 (en) * | 2014-03-28 | 2015-10-01 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| KR20250007689A (ko) | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| SMT202100280T1 (it) | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| CN112351795A (zh) * | 2018-02-23 | 2021-02-09 | 安贝科思生物制剂公司 | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 |
| US11464840B2 (en) | 2018-02-26 | 2022-10-11 | Swey-Shen Chen | Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| MX2021005708A (es) | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| JP2022510207A (ja) * | 2018-12-02 | 2022-01-26 | フェイト セラピューティクス，インコーポレイテッド | 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| GB201909509D0 (en) * | 2019-07-02 | 2019-08-14 | Immunocore Ltd | Peptide-MHC complexes |
| EP4221752A4 (en) | 2020-09-30 | 2024-12-04 | Dren Bio, Inc. | ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF |
| CA3229447A1 (en) * | 2021-08-20 | 2023-02-23 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| EP4569117A2 (en) * | 2022-08-11 | 2025-06-18 | The Trustees of The University of Pennsylvania | Universal t cells and compositions and methods of use thereof |
| EP4688859A1 (en) * | 2023-03-24 | 2026-02-11 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| WO2026016730A1 (zh) * | 2024-07-17 | 2026-01-22 | 广州瑞风生物科技股份有限公司 | 一种突变hla-e重链、hla-e三聚体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03112487A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞 |
| JPH03112486A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112485A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| GB9725764D0 (en) * | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
-
1997
- 1997-12-04 GB GBGB9725764.6A patent/GB9725764D0/en not_active Ceased
-
1998
- 1998-12-04 AT AT98959027T patent/ATE438096T1/de not_active IP Right Cessation
- 1998-12-04 US US09/555,555 patent/US7410767B1/en not_active Expired - Fee Related
- 1998-12-04 EP EP98959027A patent/EP1036327B1/en not_active Expired - Lifetime
- 1998-12-04 WO PCT/GB1998/003686 patent/WO1999028748A2/en not_active Ceased
- 1998-12-04 EP EP09165917A patent/EP2144065A1/en not_active Withdrawn
- 1998-12-04 DE DE69841020T patent/DE69841020D1/de not_active Expired - Lifetime
- 1998-12-04 JP JP2000523554A patent/JP4336451B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-25 US US12/109,990 patent/US20080274475A1/en not_active Abandoned
- 2008-12-10 JP JP2008314107A patent/JP4437160B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-21 JP JP2009191564A patent/JP5268828B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-17 JP JP2013006244A patent/JP2013081478A/ja not_active Abandoned
-
2015
- 2015-04-10 US US14/683,835 patent/US20150361180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009106299A5 (cg-RX-API-DMAC10.html) | ||
| Orlando et al. | Analysis of chromatin structure byin VivoFormaldehyde cross-linking | |
| Tagle et al. | Magnetic bead capture of expressed sequences encoded within large genomic segments | |
| JP2854904B2 (ja) | 遺伝子の検査方法 | |
| DE3586660T2 (de) | Hybridisierungstest fuer nukleinsaeure. | |
| US20050069931A1 (en) | Non-invasive diagnostic test utilizing histone modification markers | |
| WO2002055985A3 (en) | Methods and reagents for identifying rare fetal cells in the material circulation | |
| JPH04228076A (ja) | アビジン−ビオチン開裂による一本鎖ビオチニル化核酸の調製および単離 | |
| WO2011096926A1 (en) | Methods for preparing sequencing libraries | |
| CA2425545A1 (en) | Methods of identification and isolation of polynucleotides containing nucleic acid differences | |
| DE60045796D1 (de) | Gesamt-chromosom analyse von protein-dns wechselwirkungen | |
| Slobodyanyuk et al. | Mapping mammalian 3D genomes by micro-C | |
| EP3269813A1 (en) | Method for separating nucleic acids from fepe tissue | |
| JPH0427840B2 (cg-RX-API-DMAC10.html) | ||
| WO2024138050A1 (en) | Single-nucleus high-resolution multi-modal spatial genomics | |
| US20180355437A1 (en) | Plasma/serum target enrichment | |
| JP2006517181A (ja) | Ｂｂｂ−特異的タンパク質およびその断片を同定する方法 | |
| US8105787B2 (en) | Applications of nucleic acid fragments | |
| Enkhmandakh et al. | Generation of a mouse model for a conditional inactivation of Gtf2i allele | |
| JP2004531227A5 (cg-RX-API-DMAC10.html) | ||
| Brinkman et al. | Allele-specific quantification of TNFA transcripts in rheumatoid arthritis | |
| CA3087670A1 (en) | Semi-automated research instrument system | |
| JP2003509066A5 (cg-RX-API-DMAC10.html) | ||
| JP4735926B2 (ja) | 核酸の高効率回収方法 | |
| CN103097550B (zh) | 用于分离结合至任何类型的目的核酸序列的蛋白质的方法 |